Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

42 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Prognostic importance of the 6 min walk test in light chain (AL) amyloidosis.
Cohen OC, Sathyanath A, Petrie A, Ravichandran S, Law S, Manwani R, Foard D, Sachchithanantham S, Mahmood S, Martinez-Naharro A, Fontana M, Whelan CJ, Hawkins PN, Lachmann HJ, Gillmore JD, Wechalekar AD. Cohen OC, et al. Among authors: foard d. Heart. 2022 Sep 26;108(20):1616-1622. doi: 10.1136/heartjnl-2021-320703. Heart. 2022. PMID: 35764371
Cyclophosphamide, bortezomib, and dexamethasone therapy in AL amyloidosis is associated with high clonal response rates and prolonged progression-free survival.
Venner CP, Lane T, Foard D, Rannigan L, Gibbs SD, Pinney JH, Whelan CJ, Lachmann HJ, Gillmore JD, Hawkins PN, Wechalekar AD. Venner CP, et al. Among authors: foard d. Blood. 2012 May 10;119(19):4387-90. doi: 10.1182/blood-2011-10-388462. Epub 2012 Feb 13. Blood. 2012. PMID: 22331187 Free article.
A matched comparison of cyclophosphamide, bortezomib and dexamethasone (CVD) versus risk-adapted cyclophosphamide, thalidomide and dexamethasone (CTD) in AL amyloidosis.
Venner CP, Gillmore JD, Sachchithanantham S, Mahmood S, Lane T, Foard D, Rannigan L, Gibbs SD, Pinney JH, Whelan CJ, Lachmann HJ, Hawkins PN, Wechalekar AD. Venner CP, et al. Among authors: foard d. Leukemia. 2014 Dec;28(12):2304-10. doi: 10.1038/leu.2014.218. Epub 2014 Jul 16. Leukemia. 2014. PMID: 25027514
Stringent patient selection improves outcomes in systemic light-chain amyloidosis after autologous stem cell transplantation in the upfront and relapsed setting.
Venner CP, Gillmore JD, Sachchithanantham S, Mahmood S, Lane T, Foard D, Roussel M, Rannigan L, Gibbs SDj, Pinney JH, Whelan CJ, Lachmann HJ, Hawkins PN, Wechalekar AD. Venner CP, et al. Among authors: foard d. Haematologica. 2014 Dec;99(12):e260-3. doi: 10.3324/haematol.2014.108191. Epub 2014 Sep 5. Haematologica. 2014. PMID: 25193959 Free PMC article. No abstract available.
A good clonal response to chemotherapy in AL amyloidosis is associated with improved quality of life and function at 1 year.
Carter JP, Foard D, Rannigan L, Aliaz K, Mahmood S, Sachchithanantham S, Fontana M, Quarta C, Martinez De Azcona Naharro A, Youngstein T, Rezk T, Wechalekar A, Whelan C, Lachmann H, Hawkins P, Gillmore J, Lane T. Carter JP, et al. Among authors: foard d. Amyloid. 2017 Mar;24(sup1):72-73. doi: 10.1080/13506129.2017.1295944. Amyloid. 2017. PMID: 28434320 No abstract available.
42 results